Uniqure NV 10-Q quarterly reports

uniQure N.V. reports increased cash reserves and ongoing clinical trial progress, alongside a significant net loss for Q2 2026.

uniQure N.V. reported its first-quarter 2026 financial results, highlighting increased license revenues but also a significant regulatory hurdle for its lead Huntington's disease candidate, AMT-130.

uniQure N.V. reported mixed Q3 2025 results, with a significant increase in cash from recent offerings, but a major setback in its lead Huntington's disease program, AMT-130, due to FDA feedback.

uniQure N.V. reported a reduced net loss and extended its cash runway into the second half of 2027, driven by a recent public offering and significant regulatory and clinical advancements for its lead Huntington's disease program, AMT-130, despite a decline in total revenues due to divestment.

uniQure N.V. announces its Q1 2025 financial results, highlighting progress in its gene therapy pipeline, particularly the Huntington's disease program, and providing an update on its financial position.

uniQure N.V. announced its third-quarter 2024 results, showcasing advancements in its gene therapy programs and the completion of a strategic restructuring.

uniQure N.V. reports its second quarter 2024 financial results, highlighting increased revenues and a strategic restructuring aimed at conserving capital and streamlining operations.

uniQure N.V. reported a net loss of $65.6 million for the first quarter of 2024, while advancing its gene therapy pipeline.